The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...

Motegrity is a medication used to treat chronic idiopathic constipation (CIC) in adults. The FDA has granted Competitive Generic Therapy (CGT) designation to the company's Prucalopride ...

A beautiful map is worth a thousand words. To truly understand how powerful PyGMT is, play with it online on Binder! For a quicker introduction, check out our 3 minute overview! You should see a ...

Hopefully, the approval will help prevent shortages triggered by demand for injectable weight loss drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) There is still no ...

The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who are 10 years old and up with Type 2 diabetes. The liraglutide ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 shortage. The FDA has approved the first generic of Victoza (liraglutide ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

In a move that could eventually make weight loss drugs cheaper and easier to access, the Food and Drug Administration Monday approved a second generic in the category of medications known as GLP-1s.

Constipation Awareness Month ... Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a ...

and constipation -- common with the GLP-1 receptor agonist class of drugs. In order to boost generic competition, the FDA said it's working to clarify regulatory expectations for applicants early ...

effective and high-quality generic drug products.” Nausea, diarrhea, vomiting, decreased appetite, dyspepsia, and constipation were the most commonly reported adverse events in clinical trials ...